Concepts (136)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Precancerous Conditions | 1 | 2018 | 108 | 0.65 | Why? |
| Anus Neoplasms | 1 | 2018 | 123 | 0.62 | Why? |
| Anal Canal | 1 | 2018 | 367 | 0.56 | Why? |
| Papillomaviridae | 1 | 2018 | 404 | 0.51 | Why? |
| Taiwan | 12 | 2021 | 2556 | 0.47 | Why? |
| Intestinal Mucosa | 1 | 2018 | 1046 | 0.40 | Why? |
| Papillomavirus Infections | 1 | 2018 | 861 | 0.38 | Why? |
| Reverse Transcriptase Inhibitors | 2 | 2017 | 309 | 0.29 | Why? |
| Lopinavir | 1 | 2020 | 4308 | 0.29 | Why? |
| Ritonavir | 1 | 2020 | 4212 | 0.28 | Why? |
| HIV Infections | 7 | 2018 | 11620 | 0.28 | Why? |
| Virus Shedding | 1 | 2020 | 5834 | 0.25 | Why? |
| Ribavirin | 2 | 2020 | 1182 | 0.23 | Why? |
| Hepatitis A Vaccines | 2 | 2019 | 52 | 0.23 | Why? |
| Hepatitis A | 2 | 2019 | 140 | 0.20 | Why? |
| HIV Seroprevalence | 1 | 2018 | 16 | 0.19 | Why? |
| Hepatitis A Antibodies | 1 | 2017 | 18 | 0.18 | Why? |
| Papanicolaou Test | 1 | 2018 | 65 | 0.18 | Why? |
| Hepatitis A virus | 1 | 2017 | 68 | 0.17 | Why? |
| HIV Seropositivity | 1 | 2019 | 320 | 0.16 | Why? |
| Anti-HIV Agents | 3 | 2017 | 2209 | 0.15 | Why? |
| Streptococcus pneumoniae | 1 | 2021 | 827 | 0.15 | Why? |
| Chloroquine | 2 | 2021 | 3152 | 0.15 | Why? |
| Luminescent Measurements | 1 | 2020 | 924 | 0.15 | Why? |
| Immunoassay | 2 | 2021 | 4485 | 0.14 | Why? |
| Nucleosides | 1 | 2017 | 221 | 0.14 | Why? |
| Safety | 1 | 2020 | 1583 | 0.12 | Why? |
| Papillomavirus Vaccines | 1 | 2018 | 405 | 0.12 | Why? |
| Seroconversion | 2 | 2020 | 2515 | 0.12 | Why? |
| Drug Eruptions | 1 | 2017 | 319 | 0.12 | Why? |
| Biological Specimen Banks | 1 | 2020 | 1142 | 0.12 | Why? |
| Chemical and Drug Induced Liver Injury | 1 | 2017 | 451 | 0.12 | Why? |
| Drug Combinations | 1 | 2020 | 3852 | 0.10 | Why? |
| Odds Ratio | 2 | 2021 | 5861 | 0.10 | Why? |
| Antiviral Agents | 2 | 2020 | 41703 | 0.10 | Why? |
| Viremia | 1 | 2017 | 1020 | 0.10 | Why? |
| Hepatitis C, Chronic | 1 | 2018 | 973 | 0.09 | Why? |
| Genotype | 2 | 2018 | 4697 | 0.09 | Why? |
| Prisons | 1 | 2018 | 980 | 0.09 | Why? |
| Antibodies, Viral | 5 | 2021 | 51949 | 0.09 | Why? |
| Cost-Benefit Analysis | 1 | 2018 | 2259 | 0.09 | Why? |
| Vaccination Coverage | 1 | 2018 | 1249 | 0.09 | Why? |
| Coinfection | 2 | 2018 | 6820 | 0.09 | Why? |
| Respiratory System | 1 | 2020 | 3213 | 0.08 | Why? |
| Hydroxychloroquine | 2 | 2021 | 12447 | 0.08 | Why? |
| Hepatitis C | 1 | 2018 | 1514 | 0.08 | Why? |
| Logistic Models | 2 | 2018 | 9089 | 0.08 | Why? |
| Betacoronavirus | 5 | 2020 | 204454 | 0.08 | Why? |
| Anti-Retroviral Agents | 1 | 2014 | 1099 | 0.07 | Why? |
| Epithelial Cells | 1 | 2018 | 3508 | 0.07 | Why? |
| Sulfonamides | 1 | 2014 | 1294 | 0.07 | Why? |
| Exanthema | 1 | 2014 | 1097 | 0.07 | Why? |
| Adult | 17 | 2021 | 244371 | 0.07 | Why? |
| Male | 15 | 2021 | 367725 | 0.06 | Why? |
| Oxazolidinones | 1 | 2021 | 49 | 0.06 | Why? |
| Pneumonia, Viral | 5 | 2020 | 243684 | 0.06 | Why? |
| Coronavirus Infections | 5 | 2020 | 253789 | 0.06 | Why? |
| Antibody-Producing Cells | 1 | 2021 | 66 | 0.05 | Why? |
| Aminoglycosides | 1 | 2021 | 94 | 0.05 | Why? |
| Female | 14 | 2021 | 380317 | 0.05 | Why? |
| Pneumonia | 1 | 2021 | 5652 | 0.05 | Why? |
| Tetracyclines | 1 | 2021 | 82 | 0.05 | Why? |
| Drug Therapy, Combination | 3 | 2018 | 7268 | 0.05 | Why? |
| Teicoplanin | 1 | 2021 | 191 | 0.05 | Why? |
| Cross Reactions | 2 | 2020 | 4374 | 0.05 | Why? |
| Serogroup | 1 | 2021 | 510 | 0.05 | Why? |
| Tetrazoles | 1 | 2021 | 262 | 0.05 | Why? |
| Epitopes | 2 | 2021 | 4113 | 0.04 | Why? |
| Retrospective Studies | 9 | 2021 | 105322 | 0.04 | Why? |
| Binding Sites | 2 | 2021 | 6201 | 0.04 | Why? |
| RNA, Viral | 3 | 2021 | 32276 | 0.04 | Why? |
| Middle Aged | 10 | 2021 | 270681 | 0.04 | Why? |
| Young Adult | 5 | 2021 | 93724 | 0.04 | Why? |
| Humans | 19 | 2021 | 930598 | 0.04 | Why? |
| Immunoglobulin Fab Fragments | 1 | 2020 | 556 | 0.04 | Why? |
| Heterosexuality | 1 | 2018 | 148 | 0.04 | Why? |
| Serologic Tests | 2 | 2021 | 4359 | 0.04 | Why? |
| Nucleocapsid | 1 | 2021 | 734 | 0.04 | Why? |
| False Positive Reactions | 1 | 2021 | 1338 | 0.04 | Why? |
| Prevalence | 1 | 2018 | 25773 | 0.04 | Why? |
| Pregnancy Complications, Infectious | 1 | 2021 | 11559 | 0.04 | Why? |
| Patient Participation | 1 | 2021 | 829 | 0.03 | Why? |
| Standard of Care | 1 | 2020 | 1297 | 0.03 | Why? |
| Risk Factors | 3 | 2018 | 71621 | 0.03 | Why? |
| Spike Glycoprotein, Coronavirus | 2 | 2021 | 37182 | 0.03 | Why? |
| Crystallography, X-Ray | 1 | 2020 | 2689 | 0.03 | Why? |
| Cryoelectron Microscopy | 1 | 2020 | 2372 | 0.03 | Why? |
| Early Diagnosis | 1 | 2021 | 2443 | 0.03 | Why? |
| Combined Modality Therapy | 1 | 2021 | 3395 | 0.03 | Why? |
| CD4 Lymphocyte Count | 1 | 2017 | 1517 | 0.03 | Why? |
| Drug Resistance, Bacterial | 1 | 2021 | 1414 | 0.03 | Why? |
| Darunavir | 1 | 2014 | 477 | 0.03 | Why? |
| Alanine Transaminase | 1 | 2017 | 1329 | 0.03 | Why? |
| Cross-Sectional Studies | 1 | 2018 | 53120 | 0.03 | Why? |
| Health Care Costs | 1 | 2018 | 1007 | 0.03 | Why? |
| Aspartate Aminotransferases | 1 | 2017 | 1394 | 0.02 | Why? |
| Sensitivity and Specificity | 2 | 2021 | 22971 | 0.02 | Why? |
| Protein Conformation | 1 | 2020 | 4386 | 0.02 | Why? |
| Immunoglobulin A | 1 | 2021 | 3567 | 0.02 | Why? |
| Hepacivirus | 1 | 2018 | 1509 | 0.02 | Why? |
| Pandemics | 6 | 2021 | 389249 | 0.02 | Why? |
| Sexual and Gender Minorities | 1 | 2018 | 1019 | 0.02 | Why? |
| International Cooperation | 1 | 2021 | 3436 | 0.02 | Why? |
| Antibody Formation | 1 | 2021 | 4038 | 0.02 | Why? |
| Protein Domains | 1 | 2020 | 6563 | 0.02 | Why? |
| Viral Load | 2 | 2018 | 15850 | 0.02 | Why? |
| Immunoglobulin G | 2 | 2021 | 21571 | 0.02 | Why? |
| Japan | 1 | 2020 | 6653 | 0.02 | Why? |
| Age Factors | 2 | 2018 | 21039 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2017 | 5440 | 0.02 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2021 | 7868 | 0.02 | Why? |
| Reproducibility of Results | 1 | 2020 | 11304 | 0.02 | Why? |
| Vero Cells | 1 | 2020 | 14117 | 0.02 | Why? |
| Antibodies, Neutralizing | 2 | 2021 | 25288 | 0.02 | Why? |
| Incidence | 2 | 2017 | 25622 | 0.02 | Why? |
| Immunoglobulin M | 1 | 2021 | 9091 | 0.02 | Why? |
| HIV-1 | 1 | 2018 | 3365 | 0.02 | Why? |
| Treatment Outcome | 2 | 2020 | 51732 | 0.01 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2021 | 10649 | 0.01 | Why? |
| Seroepidemiologic Studies | 1 | 2017 | 10017 | 0.01 | Why? |
| Antibodies, Monoclonal | 1 | 2021 | 8041 | 0.01 | Why? |
| Disease Outbreaks | 2 | 2020 | 27595 | 0.01 | Why? |
| Severity of Illness Index | 2 | 2020 | 48226 | 0.01 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2021 | 13720 | 0.01 | Why? |
| Hospitals | 1 | 2020 | 11793 | 0.01 | Why? |
| Case-Control Studies | 1 | 2019 | 17671 | 0.01 | Why? |
| Anti-Bacterial Agents | 1 | 2021 | 10083 | 0.01 | Why? |
| Peptidyl-Dipeptidase A | 1 | 2020 | 9659 | 0.01 | Why? |
| Aged | 3 | 2021 | 215776 | 0.01 | Why? |
| Disease Management | 1 | 2017 | 6841 | 0.01 | Why? |
| Pregnancy | 1 | 2021 | 23879 | 0.01 | Why? |
| Adolescent | 2 | 2018 | 86841 | 0.01 | Why? |
| Comorbidity | 1 | 2021 | 34796 | 0.01 | Why? |
| Time Factors | 1 | 2019 | 31397 | 0.01 | Why? |
| Child | 1 | 2021 | 70012 | 0.01 | Why? |
| Animals | 1 | 2020 | 78931 | 0.01 | Why? |
Cheng's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(136)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(199)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_